Enterome to present updated safety, immunogenicity and efficacy data from its Phase 1/2 trial of EO2401 in recurrent glioblastoma (ROSALIE study) at SITC 2022

EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to significantly activate and expand existing effector memory CD8+ T cells directed at OncoMimics™ peptides with strong cross-reactivity against tumor-associated driver antigens

Paris, France – November 7, 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces it will present updated safety, immunogencity and efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (ROSALIE trial) in an oral presentation and a poster presentation at the 37^th Society for Immunotherapy of Cancer (SITC) Annual Meeting which will be held both virtually and in person in Boston, MA, USA on November 10-12, 2022.

Oral Presentation Details – Abstract #642

Title:                    EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study

Authors:             D. Reardon et al.

Date:                   November 10, 2022

Time:                   12:03 p.m. EST

Location:            Boston Convention and Exhibition Center, Ballroom West, Concurrent Session 105

Presenter:          Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School and Clinical Director for Dana Farber Cancer Institute

Poster Presentation Details – Abstract #641

Title:                    Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1-18/ROSALIE study

Authors:             A. Maia et al.

Date:                   November 10, 2022

Location:            Boston Convention and Exhibition Center, Hall C

Presenter:          Dr Ana Maia, Tübingen University Hospital, Interfaculty Institute for Cell Biology (“IFIZ”)

The abstracts will be published at 8 a.m. EST on November 7, 2022 in The Journal for ImmunoTherapy of Cancer (JITC) supplement and via this link.